Holzer R
Wien Med Wochenschr. 1993;143(2):37-42.
The therapeutic value of a sustained-release theophylline preparation (Theospirex retard 300 mg) with administration of the daily dose once a day in the evening compared to the 2 x 1 dosage usual was investigated in 19 patients suffering from asthma symptoms manifested mainly at night. In this open randomized clinical trial, a sustained-release theophylline preparation (400 mg) which had already been used for administration once a day in the evening served as reference preparation. The single dose in the evening for both preparations was 600 mg pure theophylline. Target parameters were the level of theophylline in the blood, the pulmonary function, symptoms of asthma, and the tolerance of the two sustained-release drugs. The theophylline serum levels after 13 respectively 22 hours were 12.44 and 6.98 micrograms/ml for the reference drug and 11.72 and 7.11 micrograms/ml for Theospirex retard. Equivalence of the two drugs was shown in the parameters pulmonary function, symptoms of asthma and tolerance. This study shows that 300 mg Theospirex retard film-coated tablets are suitable for a single administration of the entire daily dose in the evening.
在19名主要在夜间出现哮喘症状的患者中,研究了一种缓释茶碱制剂(Theospirex retard 300毫克)与通常的每日2次给药相比,每晚一次服用每日剂量的治疗价值。在这项开放随机临床试验中,一种已用于每晚一次给药的缓释茶碱制剂(400毫克)用作对照制剂。两种制剂每晚的单次剂量均为600毫克纯茶碱。目标参数为血液中的茶碱水平、肺功能、哮喘症状以及两种缓释药物的耐受性。对照药物在13小时和22小时后的茶碱血清水平分别为12.44和6.98微克/毫升,Theospirex retard为11.72和7.11微克/毫升。两种药物在肺功能、哮喘症状和耐受性参数方面显示出等效性。这项研究表明,300毫克Theospirex retard薄膜包衣片适合于每晚单次服用全部每日剂量。